HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

‘Insufficient Evidence’ Ibuprofen Worsens COVID-19, Says UK Regulator

Executive Summary

Review by MHRA advisory body finds no issue with ibuprofen use in COVID-19 patients and updates advice to recommend either paracetamol or ibuprofen to treat symptoms. 

You may also be interested in...



NSAID Use By COVID Patients Not Associated With Adverse Outcomes Or Mortality – Danish Study

Study of almost 10,000 COVID-19 patients finds use of ibuprofen and other NSAIDs does not increase chance of being hospitalized, admitted to the intensive care unit, or dying.

COVID-19 Ibuprofen Fears Hit Advil Sales In GSK’s Q2

Reports that ibuprofen could worsen COVID-19 in the early months of the pandemic hit sales of GSK's leading Advil brand, contributing to a drop in pro-forma Consumer Healthcare turnover in the second quarter of 2020.

EMA Quashes Claims That Ibuprofen Worsens Infection From Coronavirus

Breaking News: The European Medicines Agency says there is no evidence that ibuprofen worsens Covid‑19 and that consumers can carry on using the drug as advised by patient information. 

Related Content

Topics

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel